Details for Patent: 9,050,335

« Back to Dashboard

Which drugs does patent 9,050,335 protect, and when does it expire?

Patent 9,050,335 protects XARTEMIS XR and is included in one NDA.

Summary for Patent: 9,050,335

Title:	Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
Abstract:	The present disclosure provides extended release pharmaceutical compositions comprising oxycodone and acetaminophen that produce a quick initial onset of analgesia, yet, maintain analgesia for about 12 hours after administration of the composition to a subject in need thereof. The pharmaceutical compositions disclosed herein also reduce the levels of acetaminophen in a subject's blood near the end of the dosing interval because the acetaminophen released by the pharmaceutical composition is being eliminated by a subjects body faster than it is being absorbed.
Inventor(s):	Krishna Devarakonda, Michael J. Giuliani, Vishal K. Gupta, Ralph A. Heasley, Susan Shelby
Assignee:	Mallinckrodt LLC
Application Number:	US13/473,586
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,050,335
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound; Device; Dosage form;

Drugs Protected by US Patent 9,050,335

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Mallinckrodt Inc	XARTEMIS XR	acetaminophen; oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	204031-001	Mar 11, 2014		DISCN	Yes	No	9,050,335		Y